Cooley advised Neurocrine on the agreement.
Neurocrine has entered into a strategic partnership agreement with Takeda to develop and commercialize potential therapies in Takeda’s early- to mid-stage pipeline for psychiatric disorders. The partnership will enhance Neurocrine’s growing pipeline of treatments and strengthen the company’s position as a leading neuroscience-focused biopharmaceutical company.
Neurocrine will develop and commercialize all pipeline compounds included in the collaboration. Under the terms of the agreement, Neurocrine will pay Takeda $120 million in upfront cash and up to $495 million in development milestones, $1.4 billion in commercial milestones and double-digit royalties on net sales.
Headquartered in San Diego, Neurocrine specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids and clinical development programs in multiple therapeutic areas.
Takeda Pharmaceutical Company Limited is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology.
The Cooley team was led by Kay Chandler (Picture) and Rena Kaminsky.
Involved fees earner: Kay Chandler – Cooley LLP; Rena Kaminsky – Cooley LLP;
Law Firms: Cooley LLP;
Clients: Neurocrine Biosciences, Inc.;
